NEW YORK, OCTOBER 3, 2013 – The limited, and often transient, effectiveness of medical therapies for hidradenitis suppurativa puts the focus on treating the lesions independently to control symptoms, according to Dr. Ginette Hinds.
Although a long list of therapies, including biologics, has shown activity in hidradenitis suppurativa, only a proportion of patients respond, and cure is uncommon, said Dr. Hinds of Johns Hopkins University, Baltimore.
Data from studies of biologics, such as tumor necrosis factor (TNF)-alpha inhibitors, provide some examples. Hidradenitis suppurativa, as an inflammatory disease of the apocrine glands, is an obvious target of anti-inflammatory agents. A randomized controlled trial associated infliximab with clinical improvement relative to placebo (J. Am. Acad. Dermatol. 2013;27:1101-8), but Dr. Hinds cautioned that the benefit is not uniform.
READ THE FULL ARTICLE HERE: Focus on lesions for hidradenitis suppurativa symptom relief : Dermatology NewsTags: Dermatology Specialist Treatment